Insider activity and company results
Exelixis, Inc. (NASDAQ: EXEL) disclosed that director Oliver Bob sold a total of 30,250 shares of common stock on February 13, 2026. The sales occurred in two separate transactions at prices between $43.61 and $43.96, producing proceeds of approximately $1.3 million. As of the report, the stock is trading at $44.46, and InvestingPro's analysis indicates the company is trading below its Fair Value.
Option exercise and holdings after transactions
The Form 4 filing also shows that Mr. Bob exercised options to purchase 9,088 shares of Exelixis common stock at an exercise price of $19.28 per share, representing a total exercise value of $175,216. After completing these transactions, Mr. Bob directly holds 21,120 shares of Exelixis common stock. That total includes 18,900 shares that are scheduled to be issued to the reporting person upon vesting of restricted stock units.
Company financial profile from InvestingPro
InvestingPro metrics included with the disclosure describe Exelixis as an $11.57 billion market capitalization company with an "excellent" financial health score. Additional highlighted metrics show a price/earnings-to-growth (PEG) ratio of 0.25 and a return on equity of 36%.
Quarterly results and analyst actions
In related company news, Exelixis reported fourth-quarter 2025 results with diluted earnings per share of $0.97. That figure outpaced the consensus estimate of $0.80, a beat of 21.25%. Revenue for the quarter was $598.66 million, which fell short of the expected $604.56 million.
Following the release, H.C. Wainwright revised its price target for Exelixis to $54.00 from $52.00 and kept a Buy rating in place, citing the earnings beat as driven by lower-than-expected tax expenses. Citizens maintained its Market Outperform rating with a $50.00 price target and signaled constructive views on the company’s cancer therapy zanzalintinib.
Context from medical meeting and sector note
Analysis cited insights from the ESMO 2025 meeting as adding useful perspective on the treatment landscape for metastatic colorectal cancer, a context that underpins optimism around zanzalintinib. The analyst commentary and the clinical discussion reflect ongoing developments in Exelixis's biopharmaceutical efforts.
Takeaway
The Form 4 disclosure details a near-term sale and an option exercise by a company director, while corporate quarterly results produced a mixed performance with an EPS beat and a modest revenue shortfall. Analyst adjustments and commentary emphasize tax-related drivers of the beat and maintain favorable ratings tied to Exelixis’s oncology portfolio.